Spots Global Cancer Trial Database for resectable
Every month we try and update this database with for resectable cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Osteosarcoma With Resectable Pulmonary Metastasis: A Retrospective Study | NCT04546243 | Osteosarcoma Me... Pulmonary Disea... Resectable Sarc... Survival | resection group radiotherapy gr... | - | Peking University People's Hospital | |
| Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | NCT03916627 | Non-small Cell ... Hepatocellular ... Head and Neck S... | cemiplimab Platinum Double... fianlimab | 18 Years - | Regeneron Pharmaceuticals | |
| Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST | NCT00500188 | Gastrointestina... | Imatinib Mesyla... | - | M.D. Anderson Cancer Center | |
| A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma | NCT01660711 | Pancreatic Aden... | 5 Fluorouracil Leucovorin Irinotecan Oxaliplatin | 18 Years - | NorthShore University HealthSystem | |
| Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer | NCT00806611 | Pancreatic Canc... | Alcohol Block | 18 Years - | Thomas Jefferson University | |
| A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer | NCT05104788 | Non-Small Cell ... | Icotinib Cisplatin Carboplatin Pemetrexed | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer | NCT01688336 | Pancreatic Canc... | FOLFIRINOX | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer | NCT00735826 | Aerodigestive T... Lung Cancer Esophageal Canc... Head and Neck C... | Vorinostat | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Osteosarcoma With Resectable Pulmonary Metastasis: A Retrospective Study | NCT04546243 | Osteosarcoma Me... Pulmonary Disea... Resectable Sarc... Survival | resection group radiotherapy gr... | - | Peking University People's Hospital | |
| Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas | NCT01048723 | Sarcoma | RAD001 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma | NCT04995094 | Pathologic Stag... | Imprime PGG Pembrolizumab | 18 Years - | HiberCell, Inc. | |
| A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma | NCT03483038 | Pancreatic Aden... | Liposomal Irino... FOLFOX regimen | 18 Years - 99 Years | University of Florida | |
| Stage IV Surgery Versus Best Medical Therapy | NCT01013623 | Stage IV Resect... | Surgery Surgery plus 2 ... best medical th... | 18 Years - | Saint John's Cancer Institute | |
| Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer | NCT02305186 | Pancreatic Canc... | Pembrolizumab Neoadjuvant Che... | 18 Years - | University of Virginia | |
| Induction FLOT With CROSS CRT for Esophageal Cancer | NCT04028167 | Adenocarcinoma ... Adenocarcinoma ... | Sequential FLOT... | 18 Years - 100 Years | University of Colorado, Denver | |
| A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma | NCT03483038 | Pancreatic Aden... | Liposomal Irino... FOLFOX regimen | 18 Years - 99 Years | University of Florida | |
| Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy | NCT03387761 | Urothelial Carc... | Ipilimumab Nivolumab | 18 Years - | The Netherlands Cancer Institute | |
| Evaluation ctDNA in Patients of Non-Small-Cell Lung Cancer Following Resection | NCT04238130 | Non-Small Cell ... | Perioperative c... | 18 Years - 75 Years | Sun Yat-sen University | |
| Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer | NCT05462496 | Pancreatic Canc... | Biopsy FOLFIRINOX Ciprofloxacin Metronidazole Pembrolizumab Surgical Resect... | 19 Years - | Icahn School of Medicine at Mount Sinai | |
| A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer | NCT05380024 | Non Small Cell ... | Ensartinib | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection | NCT05120349 | Non-Small Cell ... | Osimertinib Placebo | 18 Years - | AstraZeneca | |
| NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer | NCT06094140 | Pancreatic Canc... | Durvalumab Oxaliplatin Irinotecan Calcium folinat... Fluorouracil Pegylated G-CSF | 18 Years - | Australasian Gastro-Intestinal Trials Group | |
| Stage IV Surgery Versus Best Medical Therapy | NCT01013623 | Stage IV Resect... | Surgery Surgery plus 2 ... best medical th... | 18 Years - | Saint John's Cancer Institute | |
| Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer | NCT02305186 | Pancreatic Canc... | Pembrolizumab Neoadjuvant Che... | 18 Years - | University of Virginia | |
| Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer. | NCT00226577 | Lung Cancer | Gemcitabine Pemetrexed Surgery | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC | NCT06003673 | Hepatocellular ... | neoadjuvant the... | 18 Years - 75 Years | First Affiliated Hospital of Fujian Medical University | |
| Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer | NCT02550327 | Pancreatic Aden... | Nab-paclitaxel Gemcitabine Cisplatin Anakinra | 18 Years - | Baylor Research Institute | |
| Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas | NCT03805022 | Non-metastatic ... Resectable | Doxorubicin Ifosfamide or d... Doxorubicin Ifosfamide or d... At the discreti... | 18 Years - | Institut Bergonié | |
| A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer | NCT02662634 | Non-small Cell ... | AGS-003-LNG Carboplatin Abraxane Alimta Cisplatin Taxol Radiation Thera... | 19 Years - | GU Research Network, LLC | |
| NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer | NCT06094140 | Pancreatic Canc... | Durvalumab Oxaliplatin Irinotecan Calcium folinat... Fluorouracil Pegylated G-CSF | 18 Years - | Australasian Gastro-Intestinal Trials Group | |
| Evaluation of Preoperative Endobronchial Ultrasound (EBUS) in Non Small Cell Lung Cancer (NSCLC) | NCT00960271 | Non Small Cell ... | EBUS | 18 Years - | University Hospital, Rouen | |
| Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas | NCT03805022 | Non-metastatic ... Resectable | Doxorubicin Ifosfamide or d... Doxorubicin Ifosfamide or d... At the discreti... | 18 Years - | Institut Bergonié | |
| A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma | NCT03483038 | Pancreatic Aden... | Liposomal Irino... FOLFOX regimen | 18 Years - 99 Years | University of Florida | |
| Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer | NCT00557492 | Pancreatic Canc... | Avastin (bevaci... Gemzar (Gemcita... external beam r... | 18 Years - 80 Years | University of Pittsburgh | |
| A Phase II Study of Neoadjuvant FOLFIRINOX | NCT02178709 | Resectable Panc... | FOLFIRINOX | 18 Years - | Indiana University | |
| Neoadjuvant Versus Adjuvant Therapy in Treating Resectable Thoracic Esophageal Cancer | NCT01463501 | Esophageal Canc... | Neoadjuvant che... Adjuvant chemor... | 18 Years - 65 Years | Zhejiang Cancer Hospital | |
| Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer | NCT02794675 | Head and Neck C... Head and Neck S... | Cesium 131 | 19 Years - 90 Years | Case Comprehensive Cancer Center | |
| Evaluation of Preoperative Endobronchial Ultrasound (EBUS) in Non Small Cell Lung Cancer (NSCLC) | NCT00960271 | Non Small Cell ... | EBUS | 18 Years - | University Hospital, Rouen | |
| Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia | NCT00985777 | Pancreatic Neop... | Vitamin E δ-Toc... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL) | NCT04793932 | Pancreas Ductal... | PAXG mFOLFIRINOX short-course ch... long-course che... | 18 Years - 75 Years | Associazione Italiana per lo Studio del Pancreas | |
| Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma | NCT03035188 | Basal Cell Carc... | Vismodegib | 18 Years - | SRH Wald-Klinikum Gera GmbH | |
| Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer | NCT04643366 | Rectal Cancer | Chemotherapy Radiation Thera... | 18 Years - | Virginia Commonwealth University | |
| A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection | NCT05120349 | Non-Small Cell ... | Osimertinib Placebo | 18 Years - | AstraZeneca | |
| Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma | NCT03918252 | Mesothelioma | Nivolumab Injec... Ipilimumab Inje... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Pre-Operative Or Peri-Operative Dox Regimen In Patients With Locally Advanced Resectable Gastric Cancer | NCT01876927 | Gastric Cancer Locally Advance... | DOX 4 cycles - ... DOX 2 cycles - ... | 18 Years - 75 Years | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| EDICT - Exercise inDuced Changes In Colorectal Cancer Tissues | NCT02056691 | Colorectal Canc... | Exercise progra... Muscle biopsy | 18 Years - | The Royal Bournemouth Hospital | |
| Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas | NCT03805022 | Non-metastatic ... Resectable | Doxorubicin Ifosfamide or d... Doxorubicin Ifosfamide or d... At the discreti... | 18 Years - | Institut Bergonié | |
| Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer | NCT03794544 | Resectable Early-stage NSCLC | Durvalumab Oleclumab Monalizumab Danvatirsen | 18 Years - 102 Years | MedImmune LLC | |
| FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer | NCT01688336 | Pancreatic Canc... | FOLFIRINOX | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy | NCT03387761 | Urothelial Carc... | Ipilimumab Nivolumab | 18 Years - | The Netherlands Cancer Institute | |
| Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer | NCT00557492 | Pancreatic Canc... | Avastin (bevaci... Gemzar (Gemcita... external beam r... | 18 Years - 80 Years | University of Pittsburgh | |
| Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer | NCT05462496 | Pancreatic Canc... | Biopsy FOLFIRINOX Ciprofloxacin Metronidazole Pembrolizumab Surgical Resect... | 19 Years - | Icahn School of Medicine at Mount Sinai | |
| Induction FLOT With CROSS CRT for Esophageal Cancer | NCT04028167 | Adenocarcinoma ... Adenocarcinoma ... | Sequential FLOT... | 18 Years - 100 Years | University of Colorado, Denver | |
| Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer | NCT03794544 | Resectable Early-stage NSCLC | Durvalumab Oleclumab Monalizumab Danvatirsen | 18 Years - 102 Years | MedImmune LLC | |
| Multiparametric Quantitative MRI and Response to Neoadjuvant Radiotherapy for Soft-tissue Sarcoma | NCT05684874 | Soft Tissue Sar... Adult Soft Tiss... Resectable Soft... | Neoadjuvant RT Pre-radiotherap... Post-radiothera... Tumor resection | 18 Years - | Centre Leon Berard | |
| Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC | NCT06088771 | Non-Small Cell ... | Dupilumab Cemiplimab | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Induction FLOT With CROSS CRT for Esophageal Cancer | NCT04028167 | Adenocarcinoma ... Adenocarcinoma ... | Sequential FLOT... | 18 Years - 100 Years | University of Colorado, Denver | |
| Neoadjuvant Versus Adjuvant Therapy in Treating Resectable Thoracic Esophageal Cancer | NCT01463501 | Esophageal Canc... | Neoadjuvant che... Adjuvant chemor... | 18 Years - 65 Years | Zhejiang Cancer Hospital | |
| Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer | NCT02794675 | Head and Neck C... Head and Neck S... | Cesium 131 | 19 Years - 90 Years | Case Comprehensive Cancer Center | |
| Multiparametric Quantitative MRI and Response to Neoadjuvant Radiotherapy for Soft-tissue Sarcoma | NCT05684874 | Soft Tissue Sar... Adult Soft Tiss... Resectable Soft... | Neoadjuvant RT Pre-radiotherap... Post-radiothera... Tumor resection | 18 Years - | Centre Leon Berard | |
| Interest of a Geriatric Intervention Plan Associated to a Comprehensive Geriatric Assessment on Autonomy, Quality of Life and Survival of Patients Aged 70 Years Old and More Surgically Treated for a Resectable Cancer (Thoracic, Digestive or Urologic). Randomized Multicentric Study | NCT02000011 | Cancer | comprehensive g... Geriatric inter... | 70 Years - | Assistance Publique Hopitaux De Marseille |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
